Introduction: When Two Rare Diseases Collide
Pulmonary arterial hypertension (PAH) is a progressive and life-limiting disease defined by pathological remodeling of the pulmonary vasculature, increased pulmonary vascular resistance, and eventual right ventricular failure. Despite advances in targeted therapies, PAH remains a condition where clinical improvement is often incremental and therapeutic ceilings are quickly reached.
Hereditary hemorrhagic telangiectasia (HHT) represents a very different pathological universe. It is a genetically determined vascular disorder characterized by fragile, malformed blood vessels, recurrent bleeding, and arteriovenous malformations involving multiple organ systems. When PAH develops in the context of HHT, clinicians face a rare but exceptionally complex overlap of two vascular diseases with opposing therapeutic imperatives: one demands vasodilation and vascular remodeling control, the other punishes any intervention that increases bleeding risk.
The emergence of sotatercept—a novel activin receptor type IIA ligand trap—has altered the therapeutic landscape of PAH. By targeting dysregulated signaling within the transforming growth factor-β (TGF-β) superfamily, sotatercept introduces a disease-modifying mechanism rather than symptomatic vasodilation. Yet its use in HHT raises immediate concern: can a drug that modulates vascular growth and erythropoiesis be safely deployed in a disease defined by vascular fragility?
This article explores that question through the lens of pathophysiology, clinical reasoning, and emerging evidence, using a landmark case as a springboard for broader discussion.
Pulmonary Arterial Hypertension in HHT: A Distinct Clinical Entity
Pulmonary hypertension in HHT is not a monolithic phenomenon. Most cases arise secondary to high-output states caused by hepatic arteriovenous malformations, where excessive shunting leads to elevated pulmonary pressures. In such scenarios, pulmonary vascular resistance may be normal or only mildly elevated, and management focuses on addressing the underlying shunts.
True pulmonary arterial hypertension, however, represents a far rarer and more ominous complication of HHT. In these patients, pulmonary hemodynamics resemble idiopathic PAH, with severe elevation of pulmonary vascular resistance, progressive right ventricular dysfunction, and poor prognosis. This form is most commonly associated with mutations affecting the ALK1 (ACVRL1) or ENG genes, both integral to TGF-β signaling and vascular homeostasis.
The clinical challenge lies in the fact that conventional PAH therapies—endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, and prostacyclin analogues—carry specific risks in HHT. Many exacerbate bleeding, worsen anemia, or impair platelet function. As a result, treatment often becomes a balancing act between hemodynamic benefit and hemorrhagic harm.
The Limits of Conventional PAH Therapy in HHT
Targeted PAH therapies have transformed outcomes in idiopathic and heritable PAH, yet their application in HHT-associated PAH is constrained by safety concerns. Endothelin receptor antagonists can worsen anemia. Phosphodiesterase-5 inhibitors have been associated with increased epistaxis and gastrointestinal bleeding. Prostacyclin pathway agents possess intrinsic antiplatelet effects.
In patients with HHT, where mucosal telangiectasias and fragile vasculature are omnipresent, these side effects are not theoretical—they are often clinically significant. Over time, escalating PAH therapy may paradoxically degrade quality of life through transfusion dependence, iron deficiency, and recurrent bleeding.
The consequence is therapeutic stagnation. Patients may remain symptomatic despite maximal therapy, not because options are exhausted, but because risks prevent further escalation. This is precisely the clinical void into which sotatercept has entered.
Sotatercept: A Mechanistic Shift in PAH Treatment
Sotatercept represents a conceptual departure from traditional PAH therapies. Rather than inducing vasodilation, it functions as a ligand trap for select members of the TGF-β superfamily, including activins and growth differentiation factors. By restoring balance between pro-proliferative and anti-proliferative signaling, sotatercept targets the structural remodeling that underpins PAH progression.
Clinical trials have demonstrated marked improvements in pulmonary vascular resistance, six-minute walk distance, and functional class when sotatercept is added to background therapy. These benefits suggest true disease modification rather than transient symptomatic relief.
However, the same pathway that governs pulmonary vascular remodeling also regulates angiogenesis and erythropoiesis. Adverse events reported in broader PAH populations include telangiectasia formation, bleeding events, and increases in hemoglobin levels. In patients with HHT, these effects raise immediate red flags.
Clinical Insight from a Landmark Case
The reported case involves a middle-aged woman with genetically confirmed HHT type 1 and long-standing, severe PAH refractory to maximal medical therapy. Despite treatment with prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors, her disease progressed to the point of lung transplant evaluation.
The introduction of sotatercept marked a turning point. Within months, the patient experienced substantial improvement in exertional capacity and quality of life—an outcome that had eluded years of conventional therapy. This improvement was not subtle; it altered her functional trajectory.
Predictably, the benefit came at a cost. Epistaxis frequency increased significantly, shifting from infrequent episodes to multiple events per week. Yet paradoxically, hemoglobin levels rose rather than fell, reflecting sotatercept’s erythropoietic effects. Importantly, no new telangiectasias, thrombocytopenia, or major bleeding complications were observed.
This clinical paradox—worsened bleeding symptoms alongside improved hematologic parameters and functional status—captures the essence of sotatercept’s dual nature.
Interpreting the Bleeding Risk: Nuance Over Fear
Bleeding is the defining complication of HHT, and any therapy that exacerbates it demands scrutiny. In this case, epistaxis worsened quantitatively but remained manageable. Severity scores suggested moderate impact, and standard supportive measures were sufficient.
Crucially, bleeding did not translate into anemia or clinical deterioration. On the contrary, the patient’s hemoglobin increased, likely due to sotatercept-induced stimulation of erythropoiesis. This effect has been documented in other disease contexts and may partially offset chronic blood loss in HHT.
The key lesson is not that bleeding risk should be ignored, but that it must be contextualized. In advanced PAH, functional decline and mortality risk may outweigh moderate increases in mucosal bleeding—particularly when bleeding remains controllable and reversible.
A New Risk–Benefit Equation in HHT-Associated PAH
The introduction of sotatercept forces clinicians to rethink traditional risk–benefit calculations. Historically, therapies increasing bleeding risk were avoided almost reflexively in HHT. This case suggests that such avoidance may not always serve the patient’s best interests.
In treatment-resistant PAH, the alternative to sotatercept may not be a safer drug, but disease progression, transplant dependency, or death. When viewed through this lens, tolerable bleeding may represent an acceptable trade-off for meaningful improvement in functional status and quality of life.
This does not imply indiscriminate use. Rather, it argues for individualized decision-making grounded in patient priorities, close monitoring, and multidisciplinary care involving pulmonology, hematology, and otolaryngology.
Monitoring and Practical Considerations
If sotatercept is considered in HHT-associated PAH, vigilant monitoring is essential. Baseline assessment of bleeding history, hemoglobin levels, platelet counts, and iron status should precede initiation. Early follow-up is critical, as bleeding events appear most likely during the initial treatment phase.
Management strategies for epistaxis—including humidification, topical therapies, antifibrinolytics, and ENT interventions—should be proactively integrated rather than reactively deployed. Patient education is paramount; informed patients are better equipped to tolerate manageable side effects when benefits are clear.
Equally important is the recognition that not all HHT patients will respond similarly. Genetic background, extent of telangiectatic disease, and prior bleeding burden may influence risk.
Broader Implications for PAH Therapy
Beyond HHT, this case underscores a broader shift in PAH management. Sotatercept exemplifies a new class of therapies that address vascular remodeling rather than vascular tone. As such agents enter clinical practice, traditional contraindications may require reevaluation.
For rare disease populations, case reports remain valuable—not as definitive evidence, but as signals that expand therapeutic imagination. This first documented use of sotatercept in HHT-associated PAH does precisely that.
Conclusion: Cautious Optimism at the Edge of Innovation
Sotatercept represents a promising therapeutic advance in pulmonary arterial hypertension, including in patients with complex comorbidities such as hereditary hemorrhagic telangiectasia. This case demonstrates that meaningful clinical improvement is possible even after exhaustion of conventional therapies.
The accompanying increase in bleeding highlights the need for caution, monitoring, and individualized care—but it does not negate the drug’s potential value. In selected patients, the benefits may decisively outweigh the risks.
As with all innovation at the margins of evidence, humility and vigilance are essential. Yet progress in rare and devastating diseases often begins precisely where conventional comfort ends.
FAQ
Is sotatercept safe for all patients with HHT and PAH?
No. Safety data are limited, and use should be restricted to carefully selected patients with close monitoring for bleeding and hematologic effects.
Does sotatercept worsen bleeding in HHT?
It may increase the frequency of epistaxis, but severity varies. In reported experience, bleeding has been manageable and did not necessarily lead to anemia.
Should sotatercept be considered before lung transplantation?
In treatment-resistant PAH, sotatercept may offer meaningful improvement and could be considered prior to or alongside transplant evaluation on a case-by-case basis.
